Lantern Pharma's HARMONIC trial for LP-300 demonstrated an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with enrollment expanding in Japan and Taiwan where never-smokers represent up to 40% of NSCLC cases.